Modular peptide-tag adaptor CAR T system shows potent tumour control in preprint
Start here
A bioRxiv preprint posted on 22 October 2026 describes BRiDGE CAR, a modular CAR T cell platform from the Biosceptre team that uses peptide-tag adaptors to redirect T cells against tumour antigens. The work systematically analyzes how CAR architecture and adaptor configuration affect function, testing hinge lengths and adaptor valency. The strongest combination — a medium-length hinge paired with a full-length bivalent adaptor — delivered potent activity against multiple tumour antigens and controlled tumour growth across all tested xenograft models. As a preprint, the findings have not yet been peer reviewed, and no clinical data are available.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- biorxiv.orgPickDevelopment and design rules for a modular human peptide-tag adaptor CAR T cell system
The Biosceptre team presents the BRiDGE CAR modular platform in a bioRxiv preprint and systematically analyzes how CAR and adaptor configurations affect function. A medium-length hinge combined with a full-length bivalent adaptor produced potent activity across multiple tumour antigens and controlled tumour growth across all tested xenograft models.
Heat trend for this story
Heat now 6·Peak in the comparable set 7 (Oct 22 23:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.